Concerto HealthAI is a technology leader in Definitive Real-world Data (RWD) and AI solutions for precision oncology. Concerto HealthAI, offers a clinical insight generation platform that employs real-world data in its analyses.
Concerto HealthAI’s focus is to revolutionize clinical and outcomes research to accelerate the insights and outcomes benefitting patient treatment. Concerto HealthAI is a SymphonyAI company.
Through partnerships with ASCO’s CancerLinQ®, the FDA and a range of healthcare providers, Concerto HealthAI has harnessed the abilities of AI and RWD to improve and expand clinical trials, increase accessibility to new treatments and speed up clinical drug development timelines.
Concerto HealthAI recently announced a $150 million funding round and separate real-world data partnerships with Pfizer and Janssen. The company expanded its precision oncology collaboration with Pfizer to renal cell carcinoma and prostate cancer and announced a new, multi-disease artificial intelligence project with Johnson & Johnson’s Janssen division.
Concerto also launched a new digital research software platform, eurekaHealth 3.0, that will combine real-world data with AI technology to help users predict the characteristics of a patient population.
Previously, Concerto HealthAI announced agreements with:
- Astellas Pharma to help focus on and benefit patients with FLT3 mutation-positive relapsed or refractory Acute Myeloid Leukemia (AML).
- BMS to cover a diverse range of cancers, integrate multiple data sources, and apply AI and machine learning to accelerate clinical trials, enable robust protocol design and generate insights for precision treatment and improved patient outcomes.
Takeaway: Concerto HealthAI is accelerating the number of pharma partnerships to remain a leader in the growing market for real-world data analyses.